PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'AbbVie Ltd, Maidenhead, United Kingdom. Electronic address: esteban.herreromartinez@abbvie.com.\', \'Gilead Sciences, Uxbridge, United Kingdom. Electronic address: nasir.hussain2@gilead.com.\', \'Celgene, a Bristol Myers Squibb company, Boudry, Switzerland. Electronic address: Nadege.LeRoux@bms.com.\', \'Pfizer Research and Development Ltd, Tadworth, United Kingdom. Electronic address: Judith.C.Macdonald@pfizer.com.\', \'Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: mayer_mark@lilly.com.\', \'F. Hoffmann-La Roche, Basel, Switzerland. Electronic address: rodrigo.palacios@roche.com.\', \'Global Regulatory Affairs, Sanofi R&D, Chilly Mazarin, France. Electronic address: thomas.kuhler@sanofi.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0149-2918(21)00456-210.1016/j.clinthera.2021.11.001
?:hasPublicationType
?:journal
  • Clinical therapeutics
is ?:pmid of
?:pmid
?:pmid
  • 34848082
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.151
?:rankingScore_hIndex
  • 120
?:title
  • Dynamic Regulatory Assessment: evolving the European Regulatory Framework for the Benefit of Patients and Public Health-an EFPIA View.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34848082>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34848082>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all